title: Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
abstract: For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy
  treatment. The excision repair cross-complementing group 1 (ERCC1) plays an important role in DNA repair and
  has been related to resistance to platinum chemotherapy. This study aimed to investigate the effects of the ERCC1
  (C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-based
  chemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH). DNA was extracted
  from peripheral blood lymphocytes and the single nucleotide polymorphism of ERCC1 was genotyped using a realtime
  PCR method with the TaqMan assay. The distribution of C/C, C/T and T/T genotypes was 57.7 %, 34.6 % and
  7.7 %, respectively. The response rate to platinum-based chemotherapy in the wild type (C/C) of ERCC1 (C118T) was
  better than with the variant types (C/T and T/T) but the difference was not statistically significant (29.7% vs 9.1%,
  P=0.274). The results showed that a genetic polymorphism in ERCC1 might influence patient response to platinumbased
  chemotherapy. Further multicenter studies are now required to confirm the results of our study.
authors.affiliation: Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Email: Nutthada.A@pharm.chula.ac.th
authors.forename: Walennee
authors.initials: W
authors.lastname: Kaewbubpa
authors.forename: Nutthada
authors.initials: N
authors.lastname: Areepium
authors.forename: Virote
authors.initials: V
authors.lastname: Sriuranpong
keywords: ERCC1; SNP; platinum; non-small-cell lung cancer; response to chemotherapy